Teriflunomide
Top View
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- Aubagio® (Teriflunomide)
- Lemtrada (Alemtuzumab)
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- Role of Disease-Modifying Oral Drugs in Multiple Sclerosis: a Systematic Review with Meta-Analysis
- Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
- Cutaneous Side Effects of First / Second Line Oral Disease - Modifying Treatments in Patients with Multiple Sclerosis
- Switch Analysis of Teriflunomide from Other Multiple Sclerosis Disease Modifying Therapies Ronald O
- AUBAGIO Safely and • Effectively
- Comparative Effectiveness of Teriflunomide and Dimethyl
- Multiple Sclerosis and SARS-Cov-2 Vaccination: Considerations for Immune-Depleting Therapies
- INITIATING ORAL AUBAGIO® (Teriflunomide) THERAPY
- In This Issue
- 8/15/2020 Code(S): HCPCS J2323 SUBJECT: Tysabri (Natalizumab)
- Comparative Effectiveness of Teriflunomide Vs Dimethyl Fumarate in Multiple Sclerosis David-Axel Laplaud, Romain Casey, Laetitia Barbin, Et Al
- Summary Review
- Immunology Research Product Listing | Edition 2
- For Relapsing Forms of Multiple Sclerosis